BioCardia Files 8-K: Regulation FD & Financials
Ticker: BCDA · Form: 8-K · Filed: May 1, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
BioCardia dropped an 8-K on May 1st covering Reg FD and financials. Check it out.
AI Summary
BioCardia, Inc. filed an 8-K on May 1, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides crucial updates on regulatory disclosures and financial statements, offering insights into the company's current operational and financial standing.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, primarily containing disclosures and exhibits, without immediate significant financial or operational news.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- May 1, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is May 1, 2024.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
What was BioCardia, Inc. formerly known as?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc.
What is the Standard Industrial Classification (SIC) code for BioCardia, Inc.?
The SIC code for BioCardia, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-01 07:00:23
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240430_8k.htm (8-K) — 25KB
- ex_665074.htm (EX-99.1) — 14KB
- 0001437749-24-014059.txt ( ) — 188KB
- bcda-20240501.xsd (EX-101.SCH) — 4KB
- bcda-20240501_def.xml (EX-101.DEF) — 13KB
- bcda-20240501_lab.xml (EX-101.LAB) — 17KB
- bcda-20240501_pre.xml (EX-101.PRE) — 13KB
- bcda20240430_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On May 1, 2024, BioCardia, Inc. (the "Company") issued a press release announcing primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The data was presented in a webcast sponsored by BioCardia on April 30, 2024, by members of the Executive Steering Committee: Dr. Carl Pepine, Professor of Medicine at the University of Florida at Gainesville, and Dr. Amish Raval, Professor of Medicine at the University of Wisconsin at Madison. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated May 1, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: May 1, 2024